Acadia Pharmaceuticals Inc. (ACAD) News & EventsACADAcadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Receives EU Marketing Authorization for Daybu

Acadia Pharmaceuticals announced that the European Commission, or EC, has granted marketing authorization for Daybu for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union.

Acadia Reports Q2 Revenue of $308M, Beating Expectations

Reports revenue $308M, consensus $295.52M. "Acadia delivered an outstanding second quarter, highlighted by strong commercial execution across both DAYBUE and NUPLAZID, resulting in total revenue growth of 17% year-over-year on an adjusted basis," said Catherine Owen Adams, Chief Executive Officer of Acadia. "For DAYBUE, continued patient demand and robust uptake of STIX drove another quarter of strong performance. For NUPLAZID, we continued to see strong momentum, especially in new-to-brand prescriptions as our recently expanded sales force gained traction in the field. We remain confident that both franchises are on track to achieve our long-term ambition of approximately $1.7 billion in annual net sales in 2028. Looking ahead, we are excited about the anticipated topline results from our Phase 2 program evaluating remlifanserin in Alzheimer's disease psychosis in the September to October timeframe, which we believe represents a potentially transformational opportunity for Acadia."

NUPLAZID and DAYBUE Sales Forecast Update

Consensus $1.24B. NUPLAZID net product sales in the range of $760 to $790 million. DAYBUE global net product sales in the range of $480 to $510 million, up from the previous range of $460 to $490 million. R&D expense in the range of $355 to $380 million, down from the previous range of $385 to $410 million. SG&A expense in the range of $660 to $700 million.